457 related articles for article (PubMed ID: 20644101)
21. Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma.
Kiyota M; Kobayashi T; Fuchida S; Yamamoto-Sugitani M; Ohshiro M; Shimura Y; Mizutani S; Nagoshi H; Sasaki N; Nakayama R; Chinen Y; Sakamoto N; Uchiyama H; Matsumoto Y; Horiike S; Shimazaki C; Kuroda J; Taniwaki M
Int J Hematol; 2012 May; 95(5):516-26. PubMed ID: 22426624
[TBL] [Abstract][Full Text] [Related]
22. DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma.
Kropff M; Liebisch P; Knop S; Weisel K; Wand H; Gann CN; Berdel WE; Einsele H;
Ann Hematol; 2009 Nov; 88(11):1125-30. PubMed ID: 19274460
[TBL] [Abstract][Full Text] [Related]
23. The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy.
Boyd KD; Ross FM; Tapper WJ; Chiecchio L; Dagrada G; Konn ZJ; Gonzalez D; Walker BA; Hockley SL; Wardell CP; Gregory WM; Child JA; Jackson GH; Davies FE; Morgan GJ;
Genes Chromosomes Cancer; 2011 Oct; 50(10):765-74. PubMed ID: 21961181
[TBL] [Abstract][Full Text] [Related]
24. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study.
Segeren CM; Sonneveld P; van der Holt B; Vellenga E; Croockewit AJ; Verhoef GE; Cornelissen JJ; Schaafsma MR; van Oers MH; Wijermans PW; Fibbe WE; Wittebol S; Schouten HC; van Marwijk Kooy M; Biesma DH; Baars JW; Slater R; Steijaert MM; Buijt I; Lokhorst HM;
Blood; 2003 Mar; 101(6):2144-51. PubMed ID: 12456509
[TBL] [Abstract][Full Text] [Related]
25. Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma.
Kaufman GP; Gertz MA; Dispenzieri A; Lacy MQ; Buadi FK; Dingli D; Hayman SR; Kapoor P; Lust JA; Russell S; Go RS; Hwa YL; Kyle RA; Rajkumar SV; Kumar SK
Leukemia; 2016 Mar; 30(3):633-9. PubMed ID: 26487275
[TBL] [Abstract][Full Text] [Related]
26. Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma.
San-Miguel J; Bladé J; Shpilberg O; Grosicki S; Maloisel F; Min CK; Polo Zarzuela M; Robak T; Prasad SV; Tee Goh Y; Laubach J; Spencer A; Mateos MV; Palumbo A; Puchalski T; Reddy M; Uhlar C; Qin X; van de Velde H; Xie H; Orlowski RZ
Blood; 2014 Jun; 123(26):4136-42. PubMed ID: 24833354
[TBL] [Abstract][Full Text] [Related]
27. Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma.
Chang H; Trieu Y; Qi X; Xu W; Stewart KA; Reece D
Leuk Res; 2007 Jun; 31(6):779-82. PubMed ID: 16996589
[TBL] [Abstract][Full Text] [Related]
28. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
Sonneveld P; Goldschmidt H; Rosiñol L; Bladé J; Lahuerta JJ; Cavo M; Tacchetti P; Zamagni E; Attal M; Lokhorst HM; Desai A; Cakana A; Liu K; van de Velde H; Esseltine DL; Moreau P
J Clin Oncol; 2013 Sep; 31(26):3279-87. PubMed ID: 23897961
[TBL] [Abstract][Full Text] [Related]
29. Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone.
Harousseau JL; Palumbo A; Richardson PG; Schlag R; Dimopoulos MA; Shpilberg O; Kropff M; Kentos A; Cavo M; Golenkov A; Komarnicki M; Mateos MV; Esseltine DL; Cakana A; Liu K; Deraedt W; van de Velde H; San Miguel JF
Blood; 2010 Nov; 116(19):3743-50. PubMed ID: 20628153
[TBL] [Abstract][Full Text] [Related]
30. Bortezomib in combination with dexamethasone for a young multiple myeloma with t(8; 14).
Li JY; Wang LX; Shen WY; Lu SF; Chen LJ; Lu H
Leuk Res; 2009 Apr; 33(4):584-6. PubMed ID: 18829108
[No Abstract] [Full Text] [Related]
31. Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation.
Soverini S; Cavo M; Cellini C; Terragna C; Zamagni E; Ruggeri D; Testoni N; Tosi P; De Vivo A; Amabile M; Grafone T; Ottaviani E; Giannini B; Cangini D; Bonifazi F; Neri A; Fabris S; Tura S; Baccarani M; Martinelli G
Blood; 2003 Sep; 102(5):1588-94. PubMed ID: 12730120
[TBL] [Abstract][Full Text] [Related]
32. Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies.
Dimopoulos MA; Kastritis E; Christoulas D; Migkou M; Gavriatopoulou M; Gkotzamanidou M; Iakovaki M; Matsouka C; Mparmparoussi D; Roussou M; Efstathiou E; Terpos E
Leukemia; 2010 Oct; 24(10):1769-78. PubMed ID: 20739955
[TBL] [Abstract][Full Text] [Related]
33. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials.
Harousseau JL; Avet-Loiseau H; Attal M; Charbonnel C; Garban F; Hulin C; Michallet M; Facon T; Garderet L; Marit G; Ketterer N; Lamy T; Voillat L; Guilhot F; Doyen C; Mathiot C; Moreau P
J Clin Oncol; 2009 Dec; 27(34):5720-6. PubMed ID: 19826130
[TBL] [Abstract][Full Text] [Related]
34. Treatment of multiple myeloma: 2009 update.
Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
[TBL] [Abstract][Full Text] [Related]
35. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy.
Drach J; Ackermann J; Fritz E; Krömer E; Schuster R; Gisslinger H; DeSantis M; Zojer N; Fiegl M; Roka S; Schuster J; Heinz R; Ludwig H; Huber H
Blood; 1998 Aug; 92(3):802-9. PubMed ID: 9680348
[TBL] [Abstract][Full Text] [Related]
36. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.
Ludwig H; Adam Z; Hajek R; Greil R; Tóthová E; Keil F; Autzinger EM; Thaler J; Gisslinger H; Lang A; Egyed M; Womastek I; Zojer N
J Clin Oncol; 2010 Oct; 28(30):4635-41. PubMed ID: 20823423
[TBL] [Abstract][Full Text] [Related]
37. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.
Rosiñol L; Oriol A; Teruel AI; Hernández D; López-Jiménez J; de la Rubia J; Granell M; Besalduch J; Palomera L; González Y; Etxebeste MA; Díaz-Mediavilla J; Hernández MT; de Arriba F; Gutiérrez NC; Martín-Ramos ML; Cibeira MT; Mateos MV; Martínez J; Alegre A; Lahuerta JJ; San Miguel J; Bladé J;
Blood; 2012 Aug; 120(8):1589-96. PubMed ID: 22791289
[TBL] [Abstract][Full Text] [Related]
38. Hepatic veno-occlusive disease after tandem autologous stem cell transplantation conditioned by melphalan.
Labidi SI; Sebban C; Ghesquières H; Nicolas EV; Biron P
Int J Hematol; 2008 Oct; 88(3):291-293. PubMed ID: 18696182
[TBL] [Abstract][Full Text] [Related]
39. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.
Barlogie B; Anaissie E; van Rhee F; Haessler J; Hollmig K; Pineda-Roman M; Cottler-Fox M; Mohiuddin A; Alsayed Y; Tricot G; Bolejack V; Zangari M; Epstein J; Petty N; Steward D; Jenkins B; Gurley J; Sullivan E; Crowley J; Shaughnessy JD
Br J Haematol; 2007 Jul; 138(2):176-85. PubMed ID: 17593024
[TBL] [Abstract][Full Text] [Related]
40. Two cycles of the PS-341/bortezomib, adriamycin, and dexamethasone combination followed by autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients.
Lee JH; Lee JH; Kim DY; Kim SD; Choi Y; Kang YA; Seol M; Lee KH
Eur J Haematol; 2012 Jun; 88(6):478-84. PubMed ID: 22364526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
